The company will be able to conduct tests to determine the best ingredients and terpenes to put into its manufacturing processes

MediPharm Labs was just granted a tasty treat from Health Canada.

The Ontario-based company has received a cannabis research licence that will allow it to conduct controlled testing on humans to determine the best flavour profiles for its products.

The licence was a game-changer that would allow the cannabis-extraction company to perfect its products for human consumption, said CEO Pat McCutcheon in a press statement. “Scientific study and testing of sensory properties in our process give us a competitive edge, one that we know consumer-packaged goods companies and licence holders selling to retail will value and employ.”

Sensory testing is a vital component of the food and beverage industry that allows companies to learn from the reactions of people to the sight, taste, touch and smell of products. MediPharm will now be able to conduct such tests to determine the best ingredients and terpenes to put into its manufacturing processes.

“Canadian cannabis consumers deserve the very best experience and should expect the highest standards for taste and quality,” McCutcheon said. “They will get both when MediPharm Labs is part of the value chain.”

MediPharm has been putting its cannabis to good use of late — the company just signed a deal to provide Ontario’s Loyalist College with $100,000 worth of cannabis concentrates and other products over a four-year period. The school will use this supply to pursue projects that will focus on “cannabis product development, inform process optimization and address natural product quality, consistency and safety.”

Student field trips to MediPharm facilities will now not only be informative, but they’ll also provide plenty of subjects for sensory testing.

Want to keep up to date on what’s happening in the world of cannabis? Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.